Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generics company Par Pharmaceutical has entered into an agreement to distribute verapamil hydrochloride extended release tablets, a generic version of hypertension treatment Isoptin SR.
Subscribe to our email newsletter
Verapamil hydrochloride (HCI), a calcium channel blocker, is indicated for the management of essential hypertension. Par expects to begin shipment of the product in early 2005 and, based upon the availability of raw material, believes it could supply up to 20% of the market.
Verapamil HCl extended release tablets will be available in 120mg, 180mg and 240mg strengths.
Par has also acquired the product registration to Isoptin SR and, under the terms of the agreement, licensed the rights to FSC Laboratories Inc to market the product. Par will receive a royalty on FSC’s sales of Isoptin SR.
Par will also introduce a generic version of Isoptin. Par has the right to market, sell and distribute its generic verapamil HCl extended release tablets in the US and FSC will receive continuing royalties on Par’s sales of the product, once Par has recouped its initial investment to acquire the product registration.